AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 JUN 26 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - Infants who received diphtheria-tetanus-acellular pertussis vaccines (DTaP) produced by two different manufacturers did not experience elevated numbers of side effects or complications, according to research from Pennsylvania.
Normally, the recommended three doses of the DTaP vaccine an infant receives comes from the same manufacturer. Occasionally, this is not possible. To determine the safety of mixing vaccines from different sources, D.P. Greenberg and colleagues at the University of Pittsburgh performed a multicenter, blinded, controlled trial using the two DTaP vaccines (Tripedia, Infanrix) commercially available in the U.S.
Investigators randomly assigned the 449 infants in the study into one of three groups. Infants in the control group received Tripedia for all three vaccinations (2, 4, and 6 months of age), subjects in the second group received Tripedia at 2 and 4 months and Infanrix for the 6-month vaccination, and third group infants received Tripedia at 2 months and Infanrix for the 4- and 6-month vaccinations.
The vaccine regimens were equally effective (97-100% seroprotection) for the infants in all three groups, as measured by standard enzyme immunoassays (Interchangeability of 2 diphtheria-tetanus-acellular pertussis vaccines in ...
Source: HighBeam Research, Mixing diphtheria-tetanus-acellular pertussis vaccines (DTaP) from...